Methods and systems for detection and monitoring of neurodegenerative diseases using magnetic resonance spectroscopy
AssigneeGeneral Electric Company
InventorsIleana Hancu, Napapon Sailasuta, Ralph Eugene Hurd
Life of this patent
Estimating the term…
Abstract
A method for increasing sensitivity and/or specificity of a magnetic resonance spectroscopy imaging technique for detecting a neurodegenerative disease is provided. The method includes acquiring magnetic resonance spectroscopy data from the brain of a subject, while suppressing certain metabolites in the spectrum via a data acquisition protocol, to improve quantification accuracy for the remaining metabolites, and quantifying a metabolite concentration or a metabolite concentration ratio from the spectral data as an indicator of the neurodegenerative disease.
Claims23
A method for increasing sensitivity and/or specificity of a magnetic resonance spectroscopy imaging technique in detecting a neurodegenerative disease, the method comprising:
- acquiring magnetic resonance spectroscopy data from the brain of a subject, by using a data acquisition technique that suppresses resonances in a spectrum, while keeping spectral peaks from metabolites of interest in the spectrum, wherein the data acquisition technique is PRESS-J;
- quantifying a concentration or concentration ratios of a plurality of metabolites present in the spectrum;
- and
- using the concentration or concentration ratios of the metabolites of interest as an indicator of a neurodegenerative disease.
A method for increasing sensitivity/specificity of a magnetic resonance spectroscopy imaging technique, the method comprising:
- acquiring magnetic resonance spectroscopy data from the brain of a subject via PRESS-J data acquisition protocol;
- quantifying the concentrations or concentration ratios for metabolites of interest from the spectral data;
- and
- selecting a representative metabolite of interest or a representative ratio of the metabolites of interest as an indicator of a neurodegenerative disease.
A method for aiding a clinical trial for treatment of a neurodegenerative disease, the method comprising:
- acquiring magnetic resonance spectroscopy data of the brain of a subject by using a data acquisition technique that suppresses resonances in a spectrum to improve quantification accuracy for metabolites of interest in the spectrum, wherein the data acquisition technique is PRESS-J;
- quantifying metabolite concentrations or metabolite concentration ratios for at least N-acetyl aspartate and/or and N-acetyl aspartate/Creatine from the spectral data as an indicator of a neurodegenerative disease;
- administering a pharmaceutical agent to the subject;
- and
- monitoring a change in the metabolite concentration or metabolite concentration ratio for N-acetyl aspartate and/or and N-acetyl aspartate/Creatine over time to test the effectiveness of the pharmaceutical agent.
A method for analyzing evolution of a neurodegenerative disease in a subject, the method comprising:
- acquiring magnetic resonance spectroscopy data of the brain of a subject, by using a data acquisition technique, wherein the data acquisition technique is PRESS-J, wherein magnetic resonance spectroscopy data for one or more of N-acetyl aspartate or N-acetyl aspartate/Creatine have intra-day, intra-individual coefficients of variation, respectively, of less than or equal to 2.74 or 2.57;
- quantifying a metabolite concentration or metabolite concentration ratio for at least N-acetyl aspartate and/or and N-acetyl aspartate/Creatine from the spectral data as an indicator of a neurodegenerative disease;
- and
- monitoring a change in the metabolite concentration or the metabolite concentration ratio for N-acetyl aspartate and/or and N-acetyl aspartate/Creatine over time as an indicator of evolution of the neurodegenerative disease.
A method for aiding a diagnosis of a neurodegenerative disease in a subject, the method comprising:
- acquiring magnetic resonance spectroscopy data from brain tissues of the subject, by using a data acquisition technique that suppresses resonances in a spectrum, to improve quantification accuracy for metabolites of interest, wherein the data acquisition technique is PRESS-J;
- quantifying a metabolite concentration or a metabolite concentration ratio for at least N-acetyl aspartate and/or and N-acetyl aspartate/Creatine from the spectral data as an indicator of a neurodegenerative disease;
- and
- comparing the metabolite concentration or the metabolite concentration ratio for N-acetyl aspartate and/or and N-acetyl aspartate/Creatine with a threshold value for N-acetyl aspartate and/or and N-acetyl aspartate/Creatine used for separation between a normal and a neurodegenerative state.
A method for increasing sensitivity or specificity of a magnetic resonance spectroscopy imaging technique, the method comprising:
- acquiring magnetic resonance spectroscopy data from brain tissues of a subject, by using a data acquisition technique that suppresses resonances in a spectrum, to improve quantification accuracy for metabolites of interest, wherein the data acquisition technique is PRESS-J;
- quantifying a metabolite concentration or a metabolite concentration ratio for metabolites of interest from the spectral data;
- comparing the sensitivity and specificity for each metabolite concentration or concentration ratio of interest for detecting a neurodegenerative disease;
- and
- selecting one or more representative metabolite of interest as an indicator of the neurodegenerative disease.
An MR spectroscopy system comprising:
- a set of gradient coils for producing controlled gradient field;
- a radio frequency coil for applying excitation signals to a subject of interest;
- a detecting coil for detecting magnetic resonance signals resulting from the excitation signals;
- a control and acquisition circuitry configured to energize the set of gradient coils and RF coils and to acquire magnetic resonance spectroscopy data, wherein resonances are suppressed in the spectral data via a data acquisition protocol, to improve data quantification accuracy for metabolites of interest, wherein the data acquisition protocol is PRESS-J;
- a system controller circuit configured to obtain an image having metabolite distinction from the acquired magnetic resonance spectroscopy data;
- and
- a post processing component configured for quantifying a metabolite concentration or a metabolite concentration ratio for at least N-acetyl aspartate and/or and N-acetyl aspartate/Creatine from the spectral data as an indicator of a neurodegenerative disease.
A memory circuit for storing computer instructions for diagnosing and treating a neurodegenerative disease, the computer instructions comprising instructions for:
- acquiring magnetic resonance spectroscopy data from brain tissues of a subject, by using a data acquisition technique that suppresses resonances in a spectrum, to improve quantification accuracy for metabolites of interest, wherein the data acquisition technique is PRESS-J;
- and
- quantifying a metabolite concentration or a metabolite concentration ratio for at least N-acetyl aspartate and/or and N-acetyl aspartate/Creatine from the spectral data as an indicator of a neurodegenerative disease.
Dependencies are inferred from the claim text.